The dopamine hypothesis states that aberrant dopamine neuron activity underlies psychosis symptoms, yet currently available antipsychotics that target dopamine D2 receptors are not always effective and often result in intolerable side effects (i.e., dyskinesias and metabolic disorders; Lieberman et al., 2005). This evidence concerns the gene DRD2 and metabolic disease.